<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115214</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00013</org_study_id>
    <nct_id>NCT05115214</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the Affera SpherePVI™ Multi-Ablation System to Treat Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>SpherePVI</acronym>
  <official_title>A Safety and Performance Assessment of the Affera SpherePVI™ Multi-Ablation System to Treat Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affera, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, multi-center study to evaluate the safety, performance, and&#xD;
      effectiveness of the Affera SpherePVI™ Multi-Ablation System for treating paroxysmal atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">October 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects experiencing a primary safety event</measure>
    <time_frame>6 months</time_frame>
    <description>The primary safety outcome is the incidence of the following serious device-related Primary Adverse Events (AEs) occurring within 7 days of the index ablation procedure:&#xD;
Death&#xD;
Myocardial infarction&#xD;
Persistent phrenic nerve palsy&#xD;
Transient ischemic attack (TIA)&#xD;
Stroke/cerebrovascular accident (CVA)&#xD;
Thromboembolism&#xD;
Major vascular access complications / bleeding&#xD;
Heart block&#xD;
Gastroparesis&#xD;
Severe pericarditis&#xD;
Hospitalization (initial and prolonged) due to cardiovascular or pulmonary AE&#xD;
Cardiac tamponade / perforation (up to 30 days)&#xD;
Pulmonary vein stenosis (up to 180 days)&#xD;
Atrio-esophageal fistula (up to 180 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with acute procedure success</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>The primary efficacy outcome is acute electrical isolation of all pulmonary veins using the study device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing a device- or procedure-related serious adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>The secondary safety outcome is the proportion of subjects experiencing device- or procedure-related serious adverse events (SAEs) as assessed at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product performance evaluated on a 5-point semi-quantitative scale (&quot;strongly disagree&quot; to &quot;strongly agree&quot;)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Acute product performance will be evaluated during the procedure and includes the following:&#xD;
SpherePVI™ Catheter handling sufficient to reach reasonable intended targets, as determined by the physician:&#xD;
catheter delivery to the desired ablation sites&#xD;
completion of ablation procedure&#xD;
safe removal of catheter from the subject&#xD;
Electroanatomical navigation and/or mapping sufficient to aid the procedure (if used)&#xD;
Generation of acceptable acute ablation lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects free from documented recurrence outside of the blanking period</measure>
    <time_frame>12 Months</time_frame>
    <description>Chronic efficacy will be evaluated as freedom from documented arrhythmia recurrence outside of a 90-day blanking period. Failure will be reported as both (i) recurrence of AF and (ii) recurrence of any atrial tachyarrhythmia (AF, atrial tachycardia, or atrial flutter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pulmonary veins remaining isolated at remapping</measure>
    <time_frame>75 days</time_frame>
    <description>Chronic efficacy may also be evaluated during an optional remapping procedure and will include the following:&#xD;
The number of pulmonary veins that remain isolated&#xD;
The number of patients with all pulmonary veins isolated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>SpherePVI™ Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with the SpherePVI™ Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpherePVI™ Catheter</intervention_name>
    <description>Affera SpherePVI™ Multi-Ablation System</description>
    <arm_group_label>SpherePVI™ Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic paroxysmal atrial fibrillation (PAF) documented by:&#xD;
&#xD;
               -  A physician's note indicating recurrent, self-terminating AF&#xD;
&#xD;
               -  At least two electrocardiographically documented AF episodes within 12 months&#xD;
                  prior to enrollment&#xD;
&#xD;
          2. Failure or intolerance of at least one Class I-IV anti-arrhythmic drug.&#xD;
&#xD;
          3. Suitable candidate for catheter ablation.&#xD;
&#xD;
          4. Age ≥ 18 and &lt; 75 years.&#xD;
&#xD;
          5. Able and willing to give informed consent.&#xD;
&#xD;
          6. Able and willing, and has ample means to comply with all pre-procedure, post-procedure&#xD;
             and follow-up testing requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Continuous AF lasting more than 7 days.&#xD;
&#xD;
          2. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, or&#xD;
             reversible or non-cardiac cause.&#xD;
&#xD;
          3. Previous left atrial catheter or surgical ablation (including septal closure or left&#xD;
             atrial appendage closure)&#xD;
&#xD;
          4. Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and&#xD;
             valve repair or replacement and presence of a prosthetic valve).&#xD;
&#xD;
          5. Any carotid stenting or endarterectomy.&#xD;
&#xD;
          6. Any cardiac procedure (surgical or percutaneous) or percutaneous coronary intervention&#xD;
             within 90 days prior to the initial procedure.&#xD;
&#xD;
          7. Coronary artery bypass graft (CABG) procedure within the 6 months prior to the index&#xD;
             ablation procedure.&#xD;
&#xD;
          8. Awaiting cardiac transplantation or other cardiac surgery within 12 months following&#xD;
             the initial ablation procedure.&#xD;
&#xD;
          9. Presence of any type of implantable cardiac defibrillator (with or without&#xD;
             biventricular pacing function).&#xD;
&#xD;
         10. Documented thromboembolic event (stroke or transient ischemic attack) within the past&#xD;
             6 months (180 days).&#xD;
&#xD;
         11. Documented left atrial thrombus on imaging.&#xD;
&#xD;
         12. History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
         13. Any condition contraindicating chronic anticoagulation.&#xD;
&#xD;
         14. Myocardial infarction (MI) within the 3 months (90 days) prior to the initial&#xD;
             procedure.&#xD;
&#xD;
         15. Body mass index &gt;40 kg/m2.&#xD;
&#xD;
         16. Left atrial diameter &gt;50 mm (anteroposterior).&#xD;
&#xD;
         17. Diagnosed atrial myxoma.&#xD;
&#xD;
         18. Left ventricular ejection fraction (EF) &lt; 40%.&#xD;
&#xD;
         19. Uncontrolled heart failure or NYHA Class III or IV heart failure.&#xD;
&#xD;
         20. Rheumatic heart disease.&#xD;
&#xD;
         21. Hypertrophic cardiomyopathy.&#xD;
&#xD;
         22. Unstable angina.&#xD;
&#xD;
         23. Moderate to severe mitral valve stenosis.&#xD;
&#xD;
         24. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥&#xD;
             50%, and/or effective regurgitant orifice area ≥ 0.40cm2&#xD;
&#xD;
             ).&#xD;
&#xD;
         25. Primary pulmonary hypertension.&#xD;
&#xD;
         26. Significant restrictive or obstructive pulmonary disease or chronic respiratory&#xD;
             condition.&#xD;
&#xD;
         27. Renal failure requiring dialysis.&#xD;
&#xD;
         28. Acute illness, active systemic infection, or sepsis.&#xD;
&#xD;
         29. Significant congenital anomaly or medical problem that, in the opinion of the&#xD;
             investigator, would preclude enrollment in this study or compliance with follow-up&#xD;
             requirements or would impact the scientific soundness of the clinical trial results.&#xD;
&#xD;
         30. Any woman known to be pregnant or breastfeeding, or any woman of childbearing&#xD;
             potential who is not on a reliable form of birth regulation method or abstinence.&#xD;
&#xD;
         31. Current or anticipated participation in any other clinical trial of a drug, device, or&#xD;
             biologic during the duration of the study, unless pre-approved by the Sponsor&#xD;
&#xD;
         32. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular&#xD;
             access, catheter introduction, or manipulation.&#xD;
&#xD;
         33. Known drug or alcohol dependency.&#xD;
&#xD;
         34. Life expectancy less than 12 months.&#xD;
&#xD;
         35. Vulnerable subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meital Mazor, PhD</last_name>
    <phone>18582202137</phone>
    <email>mmazor@affera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Homolka Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neužil, MD. PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute Klinicke a Experimentalni Mediciny</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Peichl, MD. PhD.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

